Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for Whom the Standard Regimen is Unsuitable
Findings from the CABASTY study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Results in Greater EFS and pCR in Patients with Resectable NSCLC Than Neoadjuvant Chemotherapy Alone
Findings from the AEGEAN study
Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR Alterations After Previous Anti–PD1(-L1) Treatment
Findings from the THOR Cohort 1 study
EMA Recommends Extending Indications for Zanubrutinib to Include Treatment of Patients with Follicular Lymphoma
New indication concerns a combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma who have received at least two prior systemic therapies
Tarlatamab Shows Promise in Patients with Previously Treated Small-Cell Lung Cancer
Findings from the DeLLphi-301 study
FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable Non-Small Cell Lung Cancer
Evidence for efficacy is based on the results from KEYNOTE-671 study
EMA Recommends Extension of Therapeutic Indications for Rucaparib
New indication concerns monotherapy for the maintenance treatment in adult patients with advanced high-grade epithelial ovarian cancer who are in response following completion of first-line platinum-based chemotherapy
FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma
Evidence for efficacy is based on the result from the CHECKMATE-76K
EMA Recommends Extension of Indications for Durvalumab in the Management of HCC
New indication concerns monotherapy in first-line treatment of adults with advanced or unresectable hepatocellular carcinoma
Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in Heavily Pretreated Patients with Advanced Breast Cancer
Findings from the U31402-A-J101 study
Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer
Findings from the HCRN GU 16–257 study
EMA Recommends Extending the Indications for Dostarlimab
New indication concerns a combination treatment with carboplatin and paclitaxel for adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer